药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Margetuximab
The risk or severity of adverse effects can be increased when Margetuximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Opicinumab
The risk or severity of adverse effects can be increased when Opicinumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Pamrevlumab
The risk or severity of adverse effects can be increased when Pamrevlumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bermekimab
The risk or severity of adverse effects can be increased when Bermekimab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Rozanolixizumab
The risk or severity of adverse effects can be increased when Rozanolixizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Refanezumab
The risk or severity of adverse effects can be increased when Refanezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bevacizumab zirconium Zr-89
The risk or severity of adverse effects can be increased when Bevacizumab zirconium Zr-89 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Emactuzumab
The risk or severity of adverse effects can be increased when Emactuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Parsatuzumab
The risk or severity of adverse effects can be increased when Parsatuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Vobarilizumab
The risk or severity of adverse effects can be increased when Vobarilizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lintuzumab
The risk or severity of adverse effects can be increased when Lintuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Xentuzumab
The risk or severity of adverse effects can be increased when Xentuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Brolucizumab
The risk or severity of adverse effects can be increased when Brolucizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Codrituzumab
The risk or severity of adverse effects can be increased when Codrituzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Icrucumab
The risk or severity of adverse effects can be increased when Icrucumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Isatuximab
The risk or severity of adverse effects can be increased when Isatuximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Anetumab ravtansine is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Gancotamab
The risk or severity of adverse effects can be increased when Gancotamab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Setrusumab
The risk or severity of adverse effects can be increased when Setrusumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Camrelizumab
The risk or severity of adverse effects can be increased when Camrelizumab is combined with Belantamab mafodotin.